Comparative Pharmacology
Head-to-head clinical analysis: DEPODUR versus DURAGESIC 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPODUR versus DURAGESIC 25.
DEPODUR vs DURAGESIC-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine sulfate extended-release liposomal injection; morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The analgesic effects are mediated by activation of mu-opioid receptors in the central nervous system, leading to modulation of pain pathways.
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
Epidural: 5-15 mg as a single dose (morphine sulfate 10 mg/mL extended-release liposome injection).
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
None Documented
None Documented
The terminal elimination half-life of morphine is approximately 2-4 hours in adults. However, DEPODUR (extended-release liposomal morphine) has a prolonged half-life due to slow release from the liposomal depot, with an effective half-life of about 12-24 hours, supporting once-daily dosing.
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Morphine is primarily excreted renally, with approximately 90% of the dose eliminated in urine within 24 hours, mainly as morphine-3-glucuronide (M3G, ~50%), morphine-6-glucuronide (M6G, ~10%), and unchanged morphine (~10%). Fecal excretion accounts for less than 10%.
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic